The going-concern warning and rapidly depleting cash reserves signal imminent equity or debt financing risk, likely at dilutive terms. Despite commercial progress in product shipments and partnerships, the financial trajectory is unsustainable without capital infusion — monitor for near-term capital raise (S-1, rights offering, or convertible note issuance). The Q2 earnings call (5 PM ET today) is critical for management's financing plan and guidance on cash runway.
Price Chart
Executive Summary
Dyadic International reported Q2 2026 revenue of $961,138, essentially flat year-over-year (-0.6%), and a net loss of $2,123,884 ($-0.06 per share), widening from a $1,793,774 loss in Q2 2025. The company disclosed a material going-concern risk, stating there is substantial doubt about its ability to continue for 12 months following June 30, 2026, as cash and securities dropped to $4.8M from $8.6M at year-end 2025. While the press release highlights commercial progress and product shipments, the deteriorating cash position, widening operating loss, and explicit going-concern warning dominate the risk profile for this micro-cap biotech.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $961,138 was essentially flat year-over-year (-0.6%) vs $966,630 in Q2 2025.
- Net loss widened to $2,123,884 ($-0.06 per share) from $1,793,774 ($-0.06 per share) in Q2 2025.
- Cash, equivalents, restricted cash, and investment securities fell to $4,794,798 as of June 30, 2026, from $8,587,289 at December 31, 2025.
- Going-concern risk: substantial doubt exists about the company's ability to continue for 12 months following June 30, 2026.
- Loss from operations increased 18.8% to $2,054,204, driven by higher cost of revenue and G&A expenses.
- Revenue miss vs consensus: EPS $-0.05 was 36.4% below consensus estimate of $-0.04; revenue slightly below consensus $977K.
- Total cost of revenue surged 60.4% to $984,165, widening the gross margin deficit.
- Share count increased to 36,438,703 from 30,102,324 a year ago, reflecting equity issuance/dilution.
Financial Impact
Cash burn rate ~$5.9M/year; cash runway ~9-10 months at current spend levels
Risk Factors
- Going-concern doubt may trigger Nasdaq delisting if stock price or equity falls below continued listing standards.
- Imminent dilutive capital raise likely given $4.8M cash and $2.1M quarterly net cash burn.
- Revenue flat year-over-year with no visible path to operating profitability near-term.
- Convertible notes ($5M+) mature or convert, adding dilution pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.4200 (+0.14%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.4200 (+9.68%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.4200 (−4.74%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.4200 (+45.81%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4200 (+52.27%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.4200 (+52.27%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.4200 (−64.71%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.4200 (+46.29%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.4200 (−40.85%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.4200 (−40.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers